Introduction
============

Photoacoustic (PA) imaging and photothermal therapy (PTT) as light-induced imaging and treatment modalities have been attracted much attention very recently.[@B1]-[@B3] PA imaging exhibits high contrast of optical imaging and deep tissue penetration of ultrasound compared to fluorescence imaging.[@B4]-[@B6] Meanwhile, PTT as a noninvasive and effective approach for cancer therapy shows relatively minimal side effects and improving tumor specific killing as compared with traditional therapies.[@B7] Therefore, the integration of PA imaging and PTT treatment into a single system could provide a novel theranostic platform for cancer diagnosis and therapy. At present, several nanomaterials with excellent near-infared (NIR) light absorption properties and an efficient heat transfer mechanism have been developed as theranostic nanoagents for PA imaging and PTT, including gold nanostructures,[@B8],[@B9] copper sulfide nanoparticle,[@B11],[@B12] molybdenum disulfide nanosheet,[@B13],[@B14] carbon nanomaterials,[@B15],[@B16] polymer nanoparticles.[@B17]-[@B19] Among them, graphene as a typical representative of two-dimensional carbon material has been extensively investigated in many different fields including biomedicine.[@B20] Functional graphene oxide (GO) and reduced graphene oxide (rGO) show a high specific surface area, and can be used as carriers for both drug and gene deliveries.[@B21]-[@B23] Meanwhile, the intrinsic NIR absorbance allows GO or rGO to be used as PA and PTT agents for *in vivo* cancer imaging and therapy.[@B24] Liu *et al.* reported rGO-Fe~3~O~4~ nanocomposites as a theranostic agent for fluorescence, PA and magnetic resonance imaging-guided PTT treatments.[@B25] Our group demonstrated that rGO could be used as a combined *in vivo* PA imaging and PTT nanoagent for cancer theranostics *in vivo*.[@B26] However, the broad absorption spectrum and low photothermal conversion efficiency of GO or rGO certainly limited their PA imaging sensitivity and phototherapeutic efficiency.

To overcome these limitations, several strategies have been explored to further enhance PA imaging sensitivity and photothermal treatment efficiency *in vivo*. Yang *et al.* demonstrated an optimal of size and surface chemistry of rGO could improve its *in vivo* behaviors, resulting in high tumor retention for PTT.[@B27] Lim *et al.* reported a hybrid nanomaterial of rGO anchored gold nanorods for promoting PA imaging*in vivo*.[@B28] Recently, Chen *et al.* developed that the rGO-loaded ultrasmall gold nanorod vesicles could enhance PTT and PA effects for cancer therapy.[@B29] The combination strategy could not only increase the light absorption efficiency of rGO at the plasmon frequency, but also amplify the PA and PTT performances. Therefore, it is significantly essential to exploit highly enhanced rGO nanocomposites with synergetic light absorption properties and photothermal conversion efficiency.

Herein, we develop a new nanocomposites of indocyanine green (ICG)-loaded polydopamine-rGO (ICG-PDA-rGO) for amplifying PA and PTT effects, and highly promoting cancer theranostics. Remarkably, dopamine, a naturally reduced agent with unique properties of mimicking adhesive proteins, is used to reduce GO by undergoing self-polymerization reaction, and building an adherent polydopamine (PDA) layer coating on the surface of rGO.[@B30] The coating layer of PDA could improve the water-solubility and biocompatibility of rGO. ICG, a NIR dye approved by the U.S. Food and Drug Administration (FDA),[@B31],[@B32] is absorbed on the surface of PDA-rGO, resulting in promoting NIR absorption of PDA-rGO for enhancing PA imaging sensitivity and PTT efficiency of cancer.

Materials and methods
=====================

Materials
---------

Single layer graphene oxide sheets were purchased from Nanjing XFNano Material Tech Co., Ltd (Product No: XF002, Diameter: 1-5 μm, Thickness: 0.8-1.2 nm. Dopamine hydrochloride (98%) and ICG (99%) were from Sigma-Aldrich. Fetal bovine serum (FBS), trypsin-EDTA solution, Penicillin-streptomycin solution and Roswell Park Memorial Institute 1640 (RPMI 1640) were purchased from Gibco Life Technologies. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich. Propidium iodide (PI) and calcein-AM were obtained from Invitrogen. All chemicals were used as received without further purification unless otherwise stated. Ultrapure water (18.25 MΩ.cm, 25°C) was used to prepare all solutions.

Preparation and characterization of ICG-PDA-rGO
-----------------------------------------------

In a typical process, commercial GO powder (100 mg) was dispersed in 200 mL of 10 mM Tris-HCl solution (pH 8.5) under ultrasonication for 5 h in ice-water bath (a frequency of 20 kHz and power of 130 W VCX130, Sonics, USA), then 50 mg of dopamine hydrochloride was added and dispersed by sonication for 15 min in an ice bath. The reaction mixture was then stirred at 600 rpm for 12 h at room temperature. After that, the PDA-rGO was washed, redispersed, and dialyzed in ultrapure water for 72 h. The black powders were dried by freeze drying. To synthesize ICG-PDA-rGO, various mass ratios of PDA-rGO and ICG were prepared to stir overnight in PBS buffer (pH 7.4) followed by a dialysis in ultrapure water.

Characterizations
-----------------

Atomic force microscope (AFM) images were taken using a Nanofirst-3000 AFM. X-ray photoelectron spectroscopy (XPS) measurements were carried out with an ESCALAB 250 high performance electron spectrometer. The ultraviolet-visible (UV-Vis) absorption spectra and fluorescence emission spectra were performed by UV-Vis absorption spectrophotometer (Lambda25, PerkinElmer, USA) and fluorescence spectrophotometer (F900, Edinburgh Instruments, Ltd., U.K.; ex: 740 nm), respectively.

ICG loading efficiency measurements
-----------------------------------

To determine ICG loading in PDA-rGO, the ICG-PDA-rGO solution was diluted in 5 mL of ethyl acetate/ethanol (9:1, v/v) and sonicated for 30 min to extract ICG completely. ICG levels were determined by UV-Vis absorption spectra. ICG loading was defined as ICG content (%, w/w) = (ICG weight in ICG-PDA-rGO /PDA-rGO weight) × 100%. All the measurements were performed in triplicate.

Cells culture
-------------

BEAS-2B normal lung epithelial cells and 4T1 breast carcinoma cells were cultured in RMPI 1640 medium supplemented with 1% penicillin, 1% streptomycin, and 10% heat-inactivated fetal bovine serum (FBS) in a humidified environment of 5% CO~2~ at 37 ^o^C.

Animals and tumor model
-----------------------

Animals received care in accordance with the Guidance Suggestions for the Care and Use of Laboratory Animals. The procedures were approved by Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences Animal Care and Use Committee. Six-to-seven week old BALB/c mice were maintained under sterile conditions in small animal isolators and were housed in a group of five in standard cages with free access to food and water and a 12 h light/dark cycle. All animals acclimated to the animal facility for at least 7 days before experiments. 4T1 breast carcinoma cells were cultured under the standard conditions recommended by American Type Culture Collection. Tumors were generated by subcutaneous injection of 4×10^6^ cells in 100 μL of PBS onto the back or breast of female BALB/c mice. All possible parameters that may cause social stress, like group size, type (treated and nontreated), etc., among the experimental animals were carefully monitored and avoided. Animals were observed daily for any behavioral abnormalities and weighed weekly.

*In vitro* PTT
--------------

The PTT effects of ICG-PDA-rGO on 4T1 cells were verified using Calcein AM and propidium iodide (PI) co-staining. 4T1 cells (5×10^4^ cells per well) were seeded in 6-well plates and incubated overnight at 37 ^o^C in a humidified 5% CO~2~ atmosphere. After being rinsed with PBS (pH 7.4), the cells were incubated with GO, PDA-rGO and ICG-PDA-rGO for 48 h at 37 ^o^C respectively under the same conditions. Afterward, the cells of experimental group were rinsed again with PBS and immersed in 200 μL of fresh culture medium, and subsequently illuminated using an 808 nm laser with energy density of 0.6 W/cm^2^ for 5 min. After another 12 h incubation cells were stained with calcein-AM for visualization of live cells and with PI for visualization of dead/late apoptotic cells, according to the manufacture\'s suggested protocol (Invitrogen). Then, the cells of experimental group were rinsed again with PBS and were examined with biological inverted microscope (Olympus IX71, JPN).

The PTT effects of ICG-PDA-rGO on 4T1 cells were further verified by MTT. 4T1 cells (1× 10^4^ cells per well) were seeded in 96-well plates and incubated overnight at 37 ^o^C in a humidified 5% CO~2~ atmosphere. After being rinsed with PBS (pH 7.4), the cells were incubated with GO, PDA-rGO and ICG-PDA-rGO for 48 h at 37 ^o^C under the same conditions. Afterward, the cells of experimental group were rinsed again with PBS and immersed in 200 μL of fresh culture medium, and subsequently illuminated using an 808 nm laser with energy density of 0.6W/cm^2^ for 5 min. The laser spot was adjusted to fully cover the area of each well. After NIR laser illumination, cells were incubated for 12 h in a 5% CO~2~, 95% air humidified incubator at 37 ^o^C. Dark control group was kept under identical conditions as the experimental group except for illumination. The standard MTT assay was carried out to evaluate the cell viability.

Infrared Thermal and PA imaging
-------------------------------

BALB/c mice with 4T1 ectopic transplantation tumor and orthotopic transplantation tumor were used as the animal modal. The imaging experiments were performed when tumors reached \~50 mm^3^. The mice were intratumoral injected with PBS, GO, PDA-rGO and ICG-PDA-rGO (n = 3). The tumors were irradiated by the 808 nm laser at 0.6 W/cm^2^ for 5 min. Region temperatures and infrared thermographic maps were obtained with an infrared thermal imaging camera (Ti27, Fluke, USA). *In vivo* PA imaging was obtained with preclinical PA computerized tomography scanner (Endra Nexus 128).

*In vivo* PTT
-------------

For PTT studies, 35 mice bearing 4T1 tumors were randomly divided into seven groups. The treatment scheme is as follows: (a) PBS-laser; (b) GO; (c) PDA-rGO; (d) ICG-PDA-rGO; (e) GO-laser; (f) PDA-rGO-laser; and (g) ICG-PDA-rGO-laser. When the tumor size reached about 50 mm^3^, the photoirradiation was applied after the intratumoral injection of PDA-rGO, ICG-PDA-rGO, or free ICG (808 nm, 0.6W/cm^2^ for 5 min). The spot of laser beam was adjusted to cover the entire region of tumor. The tumor sizes and body weights were inspected every 3 days. The tumor weight was estimated using the formula, tumor volume = length×(width)^2^/2, assuming a tumor density of 1 mg/mL. The volume of tumors was evaluated by normalizing the measured values. After therapy, major organs as well as tumors were collected and sectioned to 8 μm slices for H&E staining.

Histology evaluation
--------------------

H&E staining was performed according to a protocol provided by the vendor (BBC Biochemical). Briefly, 8 μm cryogenic slides were prepared and fixed with 10% formalin for about 30 min at room temperature. After washing with running water for 5 min, the slides were treated with gradient concentrations of alcohol (100%, 95%, and 70%), each for 20 s. The hematoxylin staining was performed for about 3 min and washed with water for 1 min. The eosin staining was performed for about 1 min. The slides were washed, treated with xylene, and mounted with Canada balsam. The images were acquired on a Nikon Eclipse 90i microscope.

Results and Discussion
----------------------

Synthesis and characterization of ICG-PDA-rGO
---------------------------------------------

The preparation process of ICG-PDA-rGO was described in Figure [1](#F1){ref-type="fig"}a. Dopamine monomers were loaded on the surface of commercial GO, and spontaneously self-polymerize via Michael addition/Schiff reaction to form PDA layer coating on the surface of rGO.[@B33] The free ICG dyes were absorbed on the surface of PDA-rGO via hydrogen bond and π-π stacking interactions. Atomic force microscope (AFM) imaging showed that the size of commercial GO was less than 1.0 μm, and the thickness of GO was 0.86 nm±0.02 nm (Figure [1](#F1){ref-type="fig"}b and 1c). After reduction process, the size of ICG-PDA-rGO was not changed obviously, however, the thickness increased to over 2 nm (Figure [1](#F1){ref-type="fig"}e and 1f). The increased thickness of GO proved that PDA coated on surface of rGO. XPS spectra analysis illustrated that the values of the C-C (284.8 eV) and C-O (286.8 eV) decreased, and a new peak of C-N (285.8 eV) was observed (Figure [1](#F1){ref-type="fig"}d and 1g), further demonstrating the conversion from GO to PDA-rGO.[@B34] The ICG loading efficiency of 5.8% to 25.6% was achieved by adjusting the weight ratio of ICG/ PDA-rGO (Figure [S1](#SM1){ref-type="supplementary-material"}). The UV-Vis-NIR spectra showed the characteristic absorption peak of ICG-PDA-rGO was located at 780 nm, and the absorbance of ICG-PDA-rGO increased about 13 folds comparing with that of PDA-rGO, further exhibiting successful loading of ICG onto PDA-rGO (Figure [2](#F2){ref-type="fig"}a). Meanwhile, the fluorescence intensity of ICG-PDA-rGO at 810 nm decreased by 85.7% compared to the equal amount of free ICG (Figure [2](#F2){ref-type="fig"}b). The enhanced NIR absorption and decreased fluorescence emission of ICG-PDA-rGO were likely owing to the direct contact between ICG and PDA-rGO nanosheet and fluorescence resonance energy transfer, which was benefited for translating the light to thermal expansion/heat for PA imaging and PTT treatments by nonradioactive decay.

*In vitro* PTT effect of ICG-PDA-rGO
------------------------------------

The enhanced NIR absorption of ICG-PDA-rGO allowed for effective photothermal nanoagent for PTT. As shown in Figure [3](#F3){ref-type="fig"}a, under the same concentration (200 μL of solution with 20 mg/L) and laser irradiation (808 nm, 0.6 W/cm^2^, 5 min) conditions, the temperature of GO, PDA-rGO and ICG-PDA-rGO reached 33.7^o^C, 40.2^o^C and 54.4^o^C, respectively. The ICG-PDA-rGO exhibited more effective than pure GO, PDA-rGO respectively, and previously reported GO derivatives in terms of photothermal heating under the NIR laser irradiation.[@B35] The photothermal effect of ICG-PDA-rGO was concentration-dependent (from 2.5 mg/L to 20 mg/L), and the temperature increased monotonically with the increasing of ICG-PDA-rGO concentration (Figure [3](#F3){ref-type="fig"}b). Moreover, ICG-PDA-rGO showed higher stability than that of free ICG after continuous laser irradiaton for 4 cycles (Figure [3](#F3){ref-type="fig"}c). During the process, the color and absorption spectra of ICG-PDA-rGO were not changed obviously (Figure [3](#F3){ref-type="fig"}d). On the contrary, the serious photobleaching of free ICG was observed, and the absorbance decreased by 68% at the wavelength of 780 nm and the color of ICG solution changed from light green to brown. The results indicated that the loading ICG onto PDA-rGO enhanced PTT performance and improved the photostability of ICG, which was favorable to promote PTT *in vitro*.

*In Vitro* PA performance of ICG-PDA-rGO
----------------------------------------

Next, the PA imaging performance of the free pure GO, PDA-rGO and ICG-PDA-rGO were investigated using Nexus 128 preclinical PA imaging system with a 780 nm plus laser as an excitation light source. The NIR excited wavelength showed negligible tissue scattering and maximal penetration depth. The laser fluency at the wavelength of 780 nm was 9 mJ/cm^2^ per pulse, which is well below the 20 mJ/cm^2^ ANSI laser safety limit.[@B36] As shown in Figure [4](#F4){ref-type="fig"}a, pure GO solution exhibited relatively weak PA signal, and the PDA-rGO solution generated moderate PA signal. The ICG-PDA-rGO generated the strongest PA signals about 20 times than that of GO under the same conditions. The signal intensity was dependent on the concentration of the ICG-PDA-rGO (Figure [4](#F4){ref-type="fig"}b). Insert showed that the PA signals increased with increasing of the concentration of ICG-PDA-rGO, and the linear range is 0.5-4.0 mg/L.

*In vitro* PTT
--------------

To evaluate the cytotoxicity of the prepared GO derivatives, 4T1 breast cancer cells and human BEAS-2B normal bronchial epithelial cells were incubated with GO, PDA-rGO and ICG-PDA-rGO, respectively, at different concentrations for 48 h. The relative viabilities were determined by standard methyl thiazolyl tetrazolium (MTT) assay. No obvious cytotoxicity was observed in all treated groups, indicating the as-prepared ICG-PDA-rGO was biocompatible (Figure [5](#F5){ref-type="fig"}a and 5b). The ICG-PDA-rGO in cancer cells could induce local hyperthermia for killing cancer cells under the 808 nm NIR laser irradiation. In order to visually evaluate the *in vitro* therapeutic effect of ICG-PDA-rGO, the cells were stained with calcein-AM and PI to identify live and dead/late apoptotic cells, respectively. As shown in Figure [5](#F5){ref-type="fig"}c, cells all displayed green fluorescence in the control group, suggesting no effect of pure laser irradiation alone on 4T1 cells. In the GO and PDA-rGO treated groups, some cells were killed and displayed red fluorescence. The ICG-PDA-rGO treated group induced most of cells death and exhibited intense red fluorescence. The quantitative results of MTT assay showed that the GO, PDA-rGO and ICG-PDA-rGO treated groups induced 8.4%, 32.7% and 92.8% of 4T1 cell dead, respectively (Figure [5](#F5){ref-type="fig"}d). The results were in a good agreement with the visual imaging, which indicated a superior photothermal ablation effect of ICG-PDA-rGO in 4T1 cells.

*In vivo* PA imaging
--------------------

In present study, we used intratumoral (i.t.) delivery of ICG-PDA-rGO for the assessment of the PA imaging ability of GO derivatives in 4T1 tumor-bearing mice (Figure [6](#F6){ref-type="fig"}a). The reason for using i.t. injection is the limitation of ICG-PDA-rGO\'s lateral dimension (\<1.0 μm). However, the local delivery method also could be used to investigate the PA effects of different GO derivatives *in vivo*, which has been emerging as an effective imaging and treatment tool for many types of localized operable and inoperable solid tumors due to the high imaging sensitivity and low systemic toxic side-effects.[@B37],[@B38] As shown in Figure [6](#F6){ref-type="fig"}b, the PBS-treated group showed low PA signal, and the blood vessels in tumor area were observed owing to the existence of hemoglobin as an endogenous contrast agent.[@B39] The ICG-PDA-rGO-treated group showed stronger PA signal in tumor than that of GO and PDA-rGO-treated groups (Figure [6](#F6){ref-type="fig"}b). Quantitative results indicated that the PA signals of ICG-PDA-rGO in tumor increased approximately 4 times as compared to GO and PDA-rGO-treated groups (Figure [6](#F6){ref-type="fig"}c). It indicated the high PA imaging sensitivity of the prepared ICG-PDA-rGO in tumor.

*In vivo* PTT
-------------

Based on the PA imaging *in vivo* and PTT *in vitro*, we expected to apply ICG-PDA-rGO for imaging-guided cancer PTT *in vivo*. 4T1 breast subcutaneous and orthotopic tumor models in mice were used to evaluate the therapuetic efficiency. PBS, GO, PDA-rGO and ICG-PDA-rGO were intratumorally injected into 4T1 breast subcutaneous tumor model in mice when the tumor size grew to 50 mm^3^, respectively. Then, all mice were irradiated at the tumor site with a NIR laser (808 nm, 0.6W/cm^2^) for 5 min. The real-time temperature change of mice was analyzed using an infrared thermal camera, which provided an effective tool for monitoring the treatment process. As shown in Figure [7](#F7){ref-type="fig"}a, after the 5 min of NIR laser irradiation, the tumors treated with PBS, GO and PDA-rGO exhibited moderate increase to 29.9, 39.9 and 44.4^o^C, respectively. While the temperature of tumor treated with ICG-PDA-rGO increased rapidly to 54.6 ^o^C, which was high enough to completely ablate the malignant cells. The histopathological analysis was carried out to illustrate typical thermal damage in the tumors. As shown in Figure [7](#F7){ref-type="fig"}b, in PBS and GO-treated groups, there was no obvious tumor necrosis in histological section. On the contrary, some karyolysis and sporadic necrotic was observed in PDA-rGO-treated group. Apparent extensive cancer necrosis occurred with ICG-PDA-rGO-treated group, such as coagulative necrosis, pyknosis and karyolysis. The results indicated that PTT treatment mediated by ICG-PDA-rGO plus single NIR laser could significantly improve the therapeutic efficiency. In order to further investigate the antitumor efficiency of ICG-PDA-rGO in mice bearing 4T1, the growth rate of tumors was monitored every 3 days after treatments. The represent mice photos reflecting the tumor size change showed in Figure [S2](#SM1){ref-type="supplementary-material"}. As shown in Figure [7](#F7){ref-type="fig"}c, the mice with GO-treated showed little therapeutic efficacy in comparison with the control group. PDA-rGO-treated group had slow tumor growth rates, and tumor suppression was incomplete. On the contrary, it was worthy to note that a complete remission of tumors was observed in ICG-PDA-rGO treated group and there was no tumor recurrence with 100% of survival rate on day 40 (Figure [7](#F7){ref-type="fig"}d). During the treatments, the body weight did not obviously change, which indicated the treatments were safe and nontoxic (Figure [S3](#SM1){ref-type="supplementary-material"}).

Next, we further evaluate the PTT mediated by ICG-PDA-rGO in 4T1 orthotopic tumor model. The breast tumor grew on the mammary fat pad of mice, keeping a distance from the surface skin. As shown in Figure [8](#F8){ref-type="fig"}a, using a NIR laser irradiation, the temperature of tumor increased to 53.3 ^o^C in mice treated with ICG-PDA-rGO within 5 min, which was already sufficient to induce irreversible tumor damage. However, other groups did not show a high temperature. As shown in Figure [8](#F8){ref-type="fig"}b, the tumor was significantly inhibited by ICG-PDA-rGO after laser irradiation, which was in accordance with previous results in subcutaneous tumor model (Figure [S4](#SM1){ref-type="supplementary-material"}). Similarly, the survival rate of ICG-PDA-rGO PTT treated group were 100% after 40 days post-treatment (Figure [8](#F8){ref-type="fig"}c), and the body weight did not obviously change (Figure [8](#F8){ref-type="fig"}d). The results indicated that the ICG-PDA-rGO could also be successfully applied for tumor PTT in breast tumors with orthotopic mice models.

Biological toxicity assessment
------------------------------

The ideal theranostic nanoagents should be nontoxic or low-toxic to organs.[@B40] We have verified that the ICG-PDA-rGO showed no obvious cytotoxicity in normal cell line or 4T1 cells. Furthermore, we investigated the potential biological toxicity, histological and blood analysis in mice. The H&E staining images of major organs collected from ICG-PDA-rGO treated group, suggesting neither obvious damage nor inflammation was observed compared to the control group, which indicated there was no distinct side effect to the treated mice *in vivo* based on ICG-PDA-rGO PTT treatment (Figure [9](#F9){ref-type="fig"}). All blood panel parameters in the ICG-PDA-rGO PTT treated mice were normal, while the other groups showed slight or mild variation (Table [S1](#SM1){ref-type="supplementary-material"}). These results indicated that the ICG-PDA-rGO possessed low cytotoxicity, and being suitable for cancer photothermal theranostics.

Conclusions
===========

In summary, we have developed a new GO derivatives, ICG-PDA-rGO, for amplifying PA and PTT effects for cancer phototheranostics. The prepared PDA-rGO was able to improve the solubility and stability of rGO, efficiently absorb ICG molecules, and enhance the optical absorption in NIR wavelength. The *in vitro*, *in vivo* PA and PTT effects of ICG-PDA-rGO were significantly promoted compared to that of PDA-rGO. The ICG-PDA-rGO-mediated PTT treatments efficiently improved the anticancer effect, leading to superior tumor eradication in 4T1 breast subcutaneous and orthotopic tumor models. The further improved the novel phototheranostic platform with reduced the lateral dimension would be a promising applications in highly sensitive PA imaging and efficient cancer phototherapy, it was expected to have a prospective potential in clinical translation.
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![Synthesis and characterization of ICG-PDA-rGO. (a) Schematic illustration of the prepared process of ICG-PDA-rGO. AFM images of GO (b) and ICG-PDA-rGO (e). The AFM height analysis of GO (c) and ICG-PDA-rGO (f). The C~1s~ XPS analysis of GO (d) and ICG-PDA-rGO (g).](thnov06p1043g001){#F1}

![The optical properties of ICG-PDA-rGO. (a) UV-vis absorption spectra of GO, PDA-rGO and ICG-PDA-rGO. The inset shows photographs of GO, PDA-rGO and ICG-PDA-rGO aqueous solutions. (b) Fluorescence spectra of GO, PDA-rGO, ICG-PDA-rGO and free ICG. The arrow indicates that the fluorescence of free ICG decreased by 85.7% after loading on the surface of PDA-rGO.](thnov06p1043g002){#F2}

![The photothermal effect of ICG-PDA-rGO. (a) Photothermal heating curves of PBS, GO, PDA-rGO and ICG-PDA-rGO solutions. C~GO~=C~PDA-rGO~=C~ICG-PDA-rGO~=20 mg/L. (b) Photothermal heating curves of ICG-PDA-rGO with different concentrations. From down to up: 2.5, 5, 10, 20 mg/L. (c) Temperature evaluation of ICG-PDA-rGO and equal free ICG solutions over four laser ON/OFF cycles. (laser ON time: 5 min, laser OFF time: 5 min). (d) The UV-vis absorption spectra of free ICG and ICG-PDA-rGO solutions before and after four cycles of laser irradiation. The insets show the photographs of free ICG and ICG-PDA-rGO solutions before and after four cycles of irradiation. The laser power was 808 nm\@0.6W/cm^2^.](thnov06p1043g003){#F3}

![The optical PA imaging of ICG-PDA-rGO solution. (a) PA signal intensity and PA images of GO, PDA-rGO and ICG-PDA-rGO aqueous solutions. C~GO~=C~PDA-rGO~=C~ICG-PDA-rGO~=10 mg/L. (b) The relationship between PA signal intensity and the concentration of ICG-PDA-rGO. Insert shows the linear relationship between PA signal intensity and the concentration of ICG-PDA-rGO.](thnov06p1043g004){#F4}

![Cytotoxicity and *in vitro* PTT. Relative viability of 4T1 cells (a) and BEAS-2B cells (b) incubated with various concentrations of GO, PDA-rGO and ICG-PDA-rGO for 48h. (c) Fluorescence images of Calcein AM/PI stained 4T1 cells incubated with PBS, GO, PDA-rGO and ICG-PDA-rGO. Scale bars are 50 μm. (d) Quantitative detection of 4T1 cells viability following PTT with ICG-PDT-rGO for 5 min. Laser irradiation dose: 808 nm, 0.6W/cm^2^, 5 min. (\*)p\<0.05.](thnov06p1043g005){#F5}

![*In vivo* PA imaging of ICG-PDA-rGO. (a) Schematic illustration of i.t. injected of ICG-PDA-rGO. (b) *In vivo* PA imaging of tumor treated with PBS, GO, PDA-rGO and ICG-PDA-rGO. (C) Statistics of mean PA intensity of the samples measured from *in vivo* PA imaging. Error bars were taken from three parallel experiments. (\*)p\<0.05, (\*\*)p\<0.01.](thnov06p1043g006){#F6}

![*In vivo* cancer PTT in xenograft mice model with 4T1 breast cancer. (a) Thermal images of 4T1 tumor-bearing mice exposed to 808 nm laser (0.6W/cm^2^) after i.t. injection of PBS, GO, PDA-rGO and ICG-PDA-rGO, respectively. (b) H&E-stained images of tumor sections collected from different treated groups after 5 h treatment. (c) Tumor growth curves of different groups of 4T1 tumor-bearing mice. (d) Survival rates of mice bearing 4T1 tumors after various treatments. (\*\*)p\<0.01.](thnov06p1043g007){#F7}

![*In vivo* cancer PTT in orthotopic mice model. (a) Thermal images of 4T1 tumor-bearing mice exposed to 808 nm laser (0.6 W/cm^2^) after intratumor injection of PBS, GO, PDA-rGO and ICG-PDA-rGO, respectively. (b) Tumor growth curves of different groups of 4T1 tumor-bearing mice. (c) Survival rates of mice bearing 4T1 tumors after various treatments. (d) Body weights were measured during 18 day evaluation period in mice with different treatments. (\*\*)p\<0.01.](thnov06p1043g008){#F8}

![Representative H&E stained images of major organs including the heart, liver, spleen, lung and kidney collected from the PBS injected mice and ICG-PDA-rGO injected mice. The dose of ICG-PDA-rGO was 2 mg/kg. These images were obtained under a light microscope.](thnov06p1043g009){#F9}
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